C hronic heart failure (HF) after myocardial infarction (MI) is steadily increasing worldwide and remains a major cause of death. Mineralocorticoid receptor (MR) antagonists (MRAs) improve survival in patients with HF as illustrated by spironolactone in the RALES (Randomized Aldactone Evaluation Study) 1 trial and by eplerenone in the EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) trial, 2 which only included patients with post-MI. Recently, the EMPHASIS (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) study even showed that eplerenone is effective in slowing down the progression of mild-to-moderate HF. 3 However, MRAs are associated with side effects, such as hyperkalemia or gynecomastia; the latter is caused by the antiandrogenic properties of their steroidal structure. These adverse effects are responsible for the underuse of MRAs. 4 Understanding of the cell-specific contribution of MR to HF and of the effects of MRA on various cell subtypes will be useful for the future development of tissue-selective MR targeting approaches that would improve the benefit/risk ratio.
C hronic heart failure (HF) after myocardial infarction (MI) is steadily increasing worldwide and remains a major cause of death. Mineralocorticoid receptor (MR) antagonists (MRAs) improve survival in patients with HF as illustrated by spironolactone in the RALES (Randomized Aldactone Evaluation Study) 1 trial and by eplerenone in the EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) trial, 2 which only included patients with post-MI. Recently, the EMPHASIS (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) study even showed that eplerenone is effective in slowing down the progression of mild-to-moderate HF. 3 However, MRAs are associated with side effects, such as hyperkalemia or gynecomastia; the latter is caused by the antiandrogenic properties of their steroidal structure. These adverse effects are responsible for the underuse of MRAs. 4 Understanding of the cell-specific contribution of MR to HF and of the effects of MRA on various cell subtypes will be useful for the future development of tissue-selective MR targeting approaches that would improve the benefit/risk ratio. 5 A crucial role of cardiomyocyte MR has been demonstrated in mice with cardiomyocyte-specific MR deletion, which allows improving left ventricular (LV) function after either MI 6 or pressure overload induced by transverse aortic constriction.
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increase in blood pressure in mice 8 and activation of MR in VSMCs leads to the stiffening of carotid arteries on hypertension induced by an aldosterone/salt challenge. 9 Although spironolactone limits vascular dysfunction in the rat aorta 10 and mesenteric arteries 11 after MI, whether VSMC-MR is involved in the progressive aggravation of HF post MI is unknown, as well as its role in coronary dysfunction associated with MI.
We used mice with VSMC-specific MR deletion (MR SMKO ) 9 to assess the contribution of VSMC-MR to LV and coronary dysfunctions and to impaired myocardial perfusion post MI.
To compare the effects of MR inactivation in VSMCs with those of pharmacological MR antagonism, wild-type infarcted mice were treated with finerenone, a highly selective nonsteroidal MRA 12 that mediates end-organ protection with a lower risk of electrolyte disturbances than other MRAs and allows improving LV function in rats with post-MI HF.
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Methods
Detailed Methods are available in the online-only Data Supplement.
Mice, MI, and Treatment
Experiments conformed to the 2010/63 directive of the European Union and the Guide for Care and Use of Laboratory Animals of the US National Institute of Health (number, 85-23). MR SMKO mice (C57/ Bl6) were generated as described previously. 9 Left coronary artery ligations were performed in 8-week-old MR SMKO male mice and littermate controls under anesthesia (xylazine [3.6 mg/kg IP] plus 2% isoflurane). Analgesia was induced using buprenorphine (0.05 mg/kg SC just after induction of anesthesia and 6, 12, 24, and 48 hours post coronary artery ligation). The snare was not tied for sham-operated mice. Finerenone (1 mg/kg per day) was administered as food additive for 2 months starting the day after MI.
Statistics
Data are presented as mean±SD. For arterial studies, differences between groups were analyzed by 2-factor repeated measures ANOVA. For experiments with apocynin, superoxide dismutase (SOD) or angiotensin-II (AngII), comparisons were assessed by Student t test for each concentration of acetylcholine. For magnetic resonance imaging myocardial perfusion studies, comparisons between the conditions ±ATL307 were assessed by Student t test. For media surface (mean±SEM), comparisons were assessed by ANOVA plus Tukey test for multiple comparisons. For other experiments, comparisons with sham-CTL were assessed by Student t test and between all MI groups by ANOVA plus Tukey test. P values <0.05 were considered significant.
Results
Cardiac and Coronary Phenotype of MR SMKO Mice
The MR gene was inactivated in VSMCs of coronary vessels from MR SMKO mice. MR expression in the endothelium and global cardiac MR transcription were unaffected ( Figure S1 in the online-only Data Supplement).
Cardiac function was examined by magnetic resonance imaging. LV end-systolic and end-diastolic volumes, LV ejection fraction, stroke volume, and cardiac output were similar between MR SMKO and littermate CTL mice, showing that cardiac function was normal in MR SMKO mice (Table 1) . Moreover, in vivo pressure-volume loops showed that LV end-systolic pressure and pressure-volume relationship (ie, LV elastance; Figure  S2A ) and LV end-diastolic pressure (ie, LV filling) and LV end-diastolic pressure-volume relationship (ie, LV compliance; Figure S2B ) were not different between MR SMKO and CTL mice.
We next examined the coronary function. Endotheliumdependent relaxation of isolated arteries induced by acetylcholine was similar in MR SMKO and CTL mice ( Figure S2C , left). Preincubation with the nitric oxide (NO)-synthase inhibitor l-NG-nitroarginine abolished the relaxation response to acetylcholine in both groups, indicating that it relies on NO production by the endothelium (Figure S2C, right) . Moreover, relaxation induced by the NO-donor sodium nitroprusside (SNP) was similar in both groups, indicating that the response of VSMCs to NO was unaltered in MR SMKO mice ( Figure S2C , middle).
LV Function on MI
As expected, 2 months after MI, compared with sham-CTL, MI-CTL mice had increased LV weight and collagen density, higher LV end-systolic and end-diastolic volumes (Table 2) , lower LV end-systolic pressure ( Figure 1A ) and higher LV end-diastolic pressure ( Figure 1B ), decreased LV end-systolic pressure-volume relationship ( Figure 1A ), and increased LV end-diastolic pressure-volume relationship ( Figure 1B ), indicating impaired LV elastance and compliance, respectively. This resulted in decreased stroke volume and cardiac output in association with lower systolic peripheral blood pressure measured in conscious MI-CTL mice ( Table 2) . Infarct sizes and LV mass were similar between all MI groups ( Table 2 ). However, interstitial collagen content was decreased in the LV of MI-MR SMKO mice when compared with MI-CTL mice (Table 2; Figure 1C ). The LV end-systolic and end-diastolic volumes in MI-MR SMKO mice were not different from those in MI-CTL mice ( Table 2) . Although stroke volume, cardiac output, and peripheral systolic blood pressure were not different in MI-MR SMKO mice compared with MI-CTL mice (Table 2) , both the LV end-systolic pressure-volume relationship (elastance; Figure 1A ) and the LV end-diastolic pressure volume-relationship (compliance; Figure 1B) were improved, indicating that impairment of LV hemodynamics was attenuated in the case of VSMC-specific MR deletion.
Vascular Function and Oxidative Stress on MI
Two months after MI, both the acetylcholine-mediated and the SNP-induced relaxation showed no difference between sham-CTL, MI-CTL, and MI-MR SMKO mice in peripheral resistance arteries (mesenteric arteries; Figure S3 ). In contrast, the acetylcholine-mediated relaxation was impaired in interseptal coronary arteries isolated from MI-CTL ( Figure 2A ). This impaired response was improved in interseptal arteries from MI-MR SMKO mice when compared with MI-CTL ( Figure 2A ). In all groups, SNP-induced relaxation was similar ( Figure 2B ) and preincubation with l-NGnitroarginine abolished acetylcholine-mediated relaxation ( Figure 2C ). Histological study showed that although MI induced an increase in the LV mean media surface of coronary arteries from 20 to 200 μm in diameter, there was no difference between MI groups ( Figure 2D ).
We next questioned whether improved coronary function in MI-MR SMKO mice was related to a decrease in oxidative stress-mediated endothelial dysfunction in coronary arteries. Preincubation with the nicotinamide adenine dinucleotide phosphate oxidase inhibitor apocynin or with the antioxidant enzyme SOD, did not affect the acetylcholine-mediated relaxation of coronary arteries from sham-CTL but improved relaxation of those from MI-CTL mice ( Figure 3A and 3B). Moreover, at the highest concentration of acetylcholine, apocynin improved the relaxation of arteries from MI-MR SMKO mice to a smaller extent than in those from MI-CTL mice ( Figure 3C and 3D), indicating a lower effect of oxidative stress when MR is absent in VSMCs.
We then assessed whether VSMC-MR is able to promote oxidative stress in the coronary bed. In MI, oxidative stress is partly mediated by AngII.
14 Coronary arteries were isolated from noninfarcted mice and exposed in vitro for 1 hour to 10 −9 mol/L AngII, a dose that did not induce vasoconstriction (Table 3 ). In arteries from CTL, pre-exposure to low-dose AngII impaired acetylcholine-mediated relaxation ( Figure 4A ). This effect was abolished by the addition of SOD, underlying a role of oxidative stress production on AngII stimulation ( Figure 4B ). AngII-mediated endothelial dysfunction was absent in arteries from MR SMKO mice 
Myocardial Perfusion and Coronary Reserve After MI
Basal myocardial perfusion was impaired after MI as shown in MI-CTL ( Figure 5A ). Moreover, the adenosine type-2 receptor agonist ATL307, which dilates coronary arteries, increased perfusion in sham-CTL but not in MI-CTL mice, indicating a collapse of the coronary reserve. However, ATL307 still increased myocardial perfusion in MI-MR SMKO mice, revealing the persistence of a coronary reserve (mL mg Figure 5B ). Capillary density remained unchanged (Table 2) .
Cardiac and Coronary Effects of the Nonsteroidal MRA Finerenone
To determine the specific contribution of VSMC-MR in the effects of MR antagonism, we compared the results obtained in MI-MR SMKO mice with those obtained in control mice with MI and additional treatment for 2 months with a low-dose of finerenone (1 mg/kg per day; MI-fine).
About LV remodeling and function, less interstitial collagen was accumulated in the LV of MI-fine than in that of MI-CTL mice (Table 2; Figure 1C) , without difference in LV weight (Table 2) . LV end-systolic and end-diastolic volumes were not different in MI-fine mice from those in MI-CTL mice (Table 2) . However, LV end-systolic pressurevolume relationship ( Figure 1A ) was higher in MI-fine than in MI-CTL mice, and both LV end-diastolic pressure and Figure 2A ). There was no difference in SNP-induced relaxation ( Figure 2B ), and l-NG-nitroarginine similarly abolished acetylcholine-mediated relaxation in all groups ( Figure 2C ). In coronary arteries from MI-fine mice, acetylcholine-mediated relaxation was not further improved by apocynin or SOD, indicating that finerenone prevented oxidative stressmediated coronary endothelial dysfunction ( Figure 3A-3D) . Beyond coronary arteries, finerenone allowed reducing the LV mRNA expression of nicotinamide adenine dinucleotide phosphate oxidase type 2 in MI-fine mice ( Figure S4 ). Moreover, coronary arteries from noninfarcted mice treated with finerenone for 4 weeks were protected against the impaired acetylcholine-mediated relaxation induced by a low dose of AngII ( Figure 4D) . Finally, about the coronary reserve, ATL307 still increased perfusion in MI-fine, revealing the persistence of a coronary reserve (mL mg −1 min −1 : 3.6±0.7; P<0.01; Figure 5 ), without modification of capillary density (Table 2) .
Discussion
MR inactivation in VSMCs improved LV function and remodeling post MI, in association with preserved coronary reserve and reduced oxidative stress-mediated coronary endothelial dysfunction. The nonsteroidal MRA finerenone improved LV and coronary function post MI, and this effect partly involved MR antagonism in VSMCs.
MR inactivation restricted to VSMCs allowed diminishing LV interstitial fibrosis (measured at distance from the infarct area in microphotographs that excluded vessels) and allowed improving LV diastolic function, as illustrated by histological and LV pressure-volume loop assessments. It has been already suggested that the MR expressed in coronary arteries affects myocardial fibrosis. Indeed, endothelial-specific MR deletion allows reducing myocardial collagen deposition after deoxycorticosterone/salt treatment in mice. 15 Moreover, the activation of VSMC-MR triggers collagen synthesis in aortas of rats or mice after aldosterone infusion. 16 This study indicates that VSMC-MR is 1 additional contributor to the adverse effects post MI, at least next cardiomyocyte MR whose role was already well established. Indeed, in mice with cardiomyocyte-specific MR deletion, there is major improvement of LV function and remodeling after MI, associated with lower production of myocardial/mitochondrial reactive oxygen species. 6 Our results emphasize that blocking MR in myocardium and coronary arteries both benefit cardiac function.
This study demonstrates the implication of VSMC-MR in coronary dysfunction post MI. The involvement of MR in coronary function has been suggested in mice with cardiomyocyte-specific aldosterone synthase overexpression, which present altered acetylcholine-mediated relaxation. 17 In this study, the impairment of coronary relaxation post MI was attenuated in MI-MR SMKO mice due to an improved NO bioavailability because the NO-synthase inhibitor l-NG-nitroarginine abolished the relaxation and without changes in the ability of VSMCs to relax because the NO-donor SNP induced equivalent relaxations in all groups. Moreover, the effect of apocynin or SOD to improve NO-mediated relaxation was more efficient in coronary arteries isolated from MI-CTL than from MI-MR SMKO or MI-fine mice. This suggests that a lower oxidative stress within the coronary arteries from MI-MR SMKO and MI-fine mice participated to improve the NO bioavailability.
Nevertheless, reactive oxygen species production does not only depend on VSMC-MR because in MI-fine mice, finerenone also targeted other MR-expressing cells, like endothelial cells and cardiomyocytes, resulting in further improvement of acetylcholine-induced NO-mediated relaxation of coronary arteries. Differential roles for MR-induced oxidative stress have been proposed in the literature, depending on the cell type and the vascular bed. After MI, cardiomyocyte-specific MR deletion allows blunting the increased O 2 − production in LV. 6 After aldosterone infusion, endothelial-specific MR deletion protects from impairment in NO-mediated relaxation of aortic rings but not of isolated mesenteric resistance arteries. 15 Here, we evidenced that VSMC-MR is an important contributor to post-MI oxidative stress in coronary arteries.
On the other hand, the deleterious effect of increased AngII post MI has been shown in mice. 18 Indeed, AT1 antagonism allows limiting myocardial hypertrophy and fibrosis. 19 Furthermore, MR and AngII signaling pathways are interdependent. 20 MR antagonism blunts the oxidative stress induced by AngII, 21 and VSMC-MR is mandatory for AngII-mediated increase in blood pressure. 8 To establish a link between VSMC-MR and AngIImediated oxidative stress in coronary arteries, we stimulated arteries isolated from noninfarcted mice with a low dose of AngII, unable to induce vasoconstriction but able to induce endothelial dysfunction because of enhanced oxidative stress. In such conditions, AngII-mediated endothelial dysfunction was blunted in coronary arteries from MR SMKO and finerenone-treated mice. Presumably, VSMC-MR blockage after MI allowed reducing a deleterious cross talk between AngII and MR signaling pathways.
Besides oxidative stress reduction, other mechanisms might participate to the improvement of coronary function in MR SMKO -MI mice. For example, after aldosterone/salt challenge, arterial stiffness of carotid arteries increases in wildtype mice but remains unchanged in MR SMKO mice, together with prevention of integrin Itgα5 upregulation. 9 Moreover, in isolated rat muscle arterioles, blockade by Itgα5-antibody of α5β1-integrin inhibits the constrictor response to increments of intraluminal pressure. 22 However, the implication of this specific integrin in coronary arteries remains to be determined.
The improvement in coronary function of MI-MR SMKO and MI-fine mice also concerned the maintenance of a coronary reserve. Clinically, impaired coronary reserve is associated with a 6-fold increase in the risk of mortality in patients with chest pain and normal angiography. 23 In patients with acute ST-segment-elevation MI without HF, the early administration of eplerenone within 24 hours post MI allows reducing the rate of rehospitalization. 24 An early improvement of the coronary function/reserve may participate to such benefit. Of note, in patients with diabetes mellitus without clinical cardiovascular disease, receiving an angiotensin-converting enzyme inhibitor and a calcium channel antagonist, adenosine-stimulated coronary reserve is higher after 6 weeks of treatment with eplerenone in comparison with a thiazidic diuretic. 25 This suggests an important role for MR in the regulation of the coronary reserve in different pathological contexts.
In conclusion, VSMC-MR is involved in the progression of HF post MI, at least through its direct role in oxidative stress-induced coronary endothelial dysfunction and in decreased coronary reserve. Treatment of infarcted mice with the nonsteroidal MRA finerenone 12 is associated with cardiac functional benefits, including improvements of endothelial function and maintenance of a coronary reserve. These factors may confer benefits after coronary occlusion, and finerenone may improve clinical outcome in this context.
Perspectives
The link between MR expressed in coronary arteries (ie, VSMC and endothelium) and the myocardial remodeling post MI as a consequence of the modulation of local inflammation remains to be explored. Furthermore, a better understanding of the contribution of MR activation in coronary arteries in pathologies that affect the coronary function and reserve, such as angina, MI, diastolic HF with preserved ejection fraction, or diabetes mellitus, will contribute to address the potential benefits of MR antagonism.
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